These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 10647504)

  • 21. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics.
    Cagnoni PJ; Matthes S; Day TC; Bearman SI; Shpall EJ; Jones RB
    Bone Marrow Transplant; 1999 Jul; 24(1):1-4. PubMed ID: 10435726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients.
    Hedmer M; Höglund P; Cavallin-Ståhl E; Albin M; Jönsson BA
    Int Arch Occup Environ Health; 2008 Jan; 81(3):285-93. PubMed ID: 17579883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.
    Xie H; Griskevicius L; Ståhle L; Hassan Z; Yasar U; Rane A; Broberg U; Kimby E; Hassan M
    Eur J Pharm Sci; 2006 Jan; 27(1):54-61. PubMed ID: 16183265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
    de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.
    Braybrooke JP; Slade A; Deplanque G; Harrop R; Madhusudan S; Forster MD; Gibson R; Makris A; Talbot DC; Steiner J; White L; Kan O; Naylor S; Carroll MW; Kingsman SM; Harris AL
    Clin Cancer Res; 2005 Feb; 11(4):1512-20. PubMed ID: 15746054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Xenobiotic metabolism and disposition in human lung: transcript profiling in non-tumoral and tumoral tissues.
    Leclerc J; Courcot-Ngoubo Ngangue E; Cauffiez C; Allorge D; Pottier N; Lafitte JJ; Debaert M; Jaillard S; Broly F; Lo-Guidice JM
    Biochimie; 2011 Jun; 93(6):1012-27. PubMed ID: 21376776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.
    Wang X; Zhang J; Xu T
    Toxicol Appl Pharmacol; 2007 Jan; 218(1):88-95. PubMed ID: 17156807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distribution of free and liposomal doxorubicin after isolated lung perfusion in a sarcoma model.
    Yan H; Cheng C; Haouala A; Krueger T; Ballini JP; Peters S; Decosterd LA; Letovanec I; Ris HB; Andrejevic-Blant S
    Ann Thorac Surg; 2008 Apr; 85(4):1225-32. PubMed ID: 18355500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.
    Hassan M; Svensson US; Ljungman P; Björkstrand B; Olsson H; Bielenstein M; Abdel-Rehim M; Nilsson C; Johansson M; Karlsson MO
    Br J Clin Pharmacol; 1999 Nov; 48(5):669-77. PubMed ID: 10594468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cooxidation of cyclophosphamide as an alternative pathway for its bioactivation and lung toxicity.
    Smith RD; Kehrer JP
    Cancer Res; 1991 Jan; 51(2):542-8. PubMed ID: 1985772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-performance liquid chromatographic determination of acrolein as a marker for cyclophosphamide bioactivation in human liver microsomes.
    Bohnenstengel F; Eichelbaum M; Golbs E; Kroemer HK
    J Chromatogr B Biomed Sci Appl; 1997 Apr; 692(1):163-8. PubMed ID: 9187396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of doxorubicin in isolated lung of dogs and humans perfused in vivo.
    Minchin RF; Johnston MR; Aiken MA; Boyd MR
    J Pharmacol Exp Ther; 1984 Apr; 229(1):193-8. PubMed ID: 6707934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antegrade versus retrograde isolated lung perfusion: doxorubicin uptake and distribution in a sarcoma model.
    Krueger T; Kuemmerle A; Andrejevic-Blant S; Yan H; Pan Y; Ballini JP; Klepetko W; Decosterd LA; Stupp R; Ris HB
    Ann Thorac Surg; 2006 Dec; 82(6):2024-30. PubMed ID: 17126104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens.
    Sládek NE; Kollander R; Sreerama L; Kiang DT
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):309-21. PubMed ID: 11914911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antineoplastic chemotherapy for bronchial carcinoma].
    Tanneberger S
    Arch Geschwulstforsch; 1985; 55(1):63-71. PubMed ID: 2985017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study.
    Grunberg SM; Crowley J; Hande KR; Giroux D; Munshi N; Lau DH; Schroder LE; Zangmeister MH; Balcerzak SP; Hynes HE; Gandara DR
    Cancer Chemother Pharmacol; 1999; 44(6):461-8. PubMed ID: 10550566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
    Jounaidi Y; Hecht JE; Waxman DJ
    Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
    Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
    Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients.
    Williams ML; Wainer IW; Granvil CP; Gehrcke B; Bernstein ML; Ducharme MP
    Chirality; 1999; 11(4):301-8. PubMed ID: 10224657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.